Compound for treatment of alzheimer's disease and familial dementia

Abstract

An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.

1 . An isolated protein selected from the group of proteins consisting of residues 90-236 of Bri2 from human (SEQ ID NO: 2) and the Brichos domains of Bri2 from human (SEQ ID NO: 5), chimpanzee (SEQ ID NO: 6), bovine (SEQ ID NO: 7), pig (SEQ ID NO: 8), mouse (SEQ ID NO: 9) and rat (SEQ ID NO: 10). 
     
     
         2 . An isolated protein according to  claim 1 , selected from the group of proteins consisting of residues 90-236 of Bri2 from human (SEQ ID NO: 2); and the Brichos domain of Bri2 from human (SEQ ID NO: 5). 
     
     
         3 . An isolated protein according to  claim 2 , which is consisting of residues 90-236 of Bri2 from human (SEQ ID NO: 2). 
     
     
         4 . An isolated protein according to  claim 2 , which is consisting of the Brichos domain of Bri2 from human (SEQ ID NO: 5). 
     
     
         5 - 9 . (canceled) 
     
     
         10 . A pharmaceutical composition comprising a therapeutically effective amount of an isolated protein according to  claim 1  and a suitable pharmaceutical carrier therefor. 
     
     
         11 - 28 . (canceled)